Skip to Content

Vosoritide Aids Bone Growth in Children With Dwarfism

TUESDAY, Oct. 27, 2020 -- Vosoritide increases bone growth velocity in children with achondroplasia, the most common form of dwarfism, according to a study recently published in The Lancet.

Ravi Savarirayan, M.D., from the University of Melbourne in Australia, and colleagues randomly assigned 121 children diagnosed with achondroplasia (aged 5 to 18 years) to either subcutaneous injections of vosoritide or placebo for 52 weeks.

The researchers found that the adjusted mean difference in annualized growth velocity between patients in the vosoritide group and placebo group was 1.57 cm/year, favoring vosoritide. Most patients (119 people) had at least one adverse event (98 percent in both groups). None of the serious adverse events were thought to be treatment-related, and no deaths occurred.

"It is not known whether final adult height will be increased, or what the harms of long-term therapy might be," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including BioMarin, which manufactures vosoritide and funded the study.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Vitamin D Deficiency Associated With Increased COVID-19 Risk

MONDAY, Jan. 25, 2021 -- Patients with vitamin D deficiency are significantly more likely to be positive for COVID-19, according to a study published in the April issue of...

Children Less Susceptible to SARS-CoV-2 but More Infectious

MONDAY, Jan. 25, 2021 -- Children and adolescents are less susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but are more infectious than...

Disparities in Lung Cancer Screening Eligibility Still Exist

FRIDAY, Jan. 22, 2021 -- Despite increases in lung cancer screening eligibility, gender, racial, and ethnic screening disparities may still persist, according to a study published...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.